Lumida
/DERM
⌘K
Journey Medical Corp

Journey Medical Corp

DERM
$7.23USD+1.97%+0.14 today

MARKET CAP

204.1M

P/E (TTM)

FWD P/E

DAY RANGE

$7 – $7

52W RANGE

$4
$10

AI Summary

Stalk
Sell NowMedium

DERM remains in early Stage 1 consolidation following a terminal decline and range-bound repair. A late-June breakout failed, evidenced by a Bullish Exhaustion candle, and price is overbought and facing resistance. This leads to a bearish medium-term bias, recommending selling into strength near the breakout region.

  • Q2 2026 revenue of $18.5M up 23% YoY; Adjusted EBITDA positive $2.9M
  • MROSI uptake reached ~36,000 prescriptions, contributing $8.1M revenue
  • Q2 net loss of $0.3M and negative earnings yield signal profit challenges
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$63.1M$73.7M$79.2M$55.1M$61.2M
YoY %+16.7%+7.5%-30.4%+11.1%
P / Sales0.9x0.4x1.3x1.4x3.1x
EV / Sales1.0x1.2x1.6x2.2x3.7x
Gross Profit, Adj.$31.1M$42.9M$56.3M$34.3M$40.3M
YoY %+38.1%+31.2%-39.1%+17.7%
Margin %49.2%58.2%71.1%62.1%65.8%
EV / Gross Profit2.0x2.1x2.3x3.5x5.6x
EBITDA, Adj.$-32.3M$-23.2M$4.8M$-11.3M$-4.5M
YoY %+28.1%+120.8%-332.6%+59.7%
Margin %-51.2%-31.5%6.1%-20.4%-7.4%
EV / EBITDA-1.9x-3.8x26.5x-10.6x-50.2x
EBIT$-34.9M$-27.5M$-2.1M$-14.7M$-8.8M
YoY %+21.1%+92.5%-608.0%+40.1%
Margin %-55.2%-37.4%-2.6%-26.6%-14.4%
EV / EBIT-1.7x-3.2x-61.8x-8.2x-25.9x
Net Income$-44.0M$-29.6M$-3.9M$-14.7M$-11.4M
YoY %+32.7%+87.0%-280.8%+22.1%
Net Margin-69.7%-40.2%-4.9%-26.6%-18.7%
EPS (GAAP)-$4.32-$1.69-$0.21-$0.72-$0.47
YoY %+60.9%+87.6%-242.9%+34.7%